Amicus Therapeutics Inc share price logo

Amicus Therapeutics Inc Share Price

NASDAQ: FOLD

Mid Cap

$14.46

+0.01

(+0.03%)

as on

Amicus Therapeutics Inc Stock Performance

as on April 18, 2026 at 6:59 am IST

  • Day's Low

    $14.45
    $14.46
    downward going graph

    0.07%

    Downside

  • 52 Week's Low

    52 Week's High

    $5.51
    $14.48
    downward going graph

    61.89%

    Downside

    0.14%

    Upside

    downward going graph

Amicus Therapeutics Inc share price movements today

Previous Close
$14.45
Open
$14.45
Volume
1.6M
Day's Low - High
$14.45 - $14.46
52 Week Low - High
$5.51 - $14.48

Amicus Therapeutics Inc Historical Returns

1 Month Return
+ 0.63 %
3 Month Return
+ 0.91 %
1 Year Return
+ 111.71 %
3 Year Return
+ 21.61 %
5 Year Return
+ 45.47 %

Amicus Therapeutics Inc Stock Fundamentals & Key Indicators

Check Amicus Therapeutics Inc market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

$4.5B

EPS (TTM)

0.0726

Dividend Yield

0.00%

Quarterly Earnings Growth YOY

-0.95%

PE Ratio (TTM)

0

PEG Ratio

-0.18

EBITDA

42.0M

Revenue (TTM)

634.2M

Profit Margin

-4.28%

Return On Equity TTM

-11.58%

Amicus Therapeutics Inc vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of Amicus Therapeutics Inc with its industry peers.

Company
Analyst View
Market Cap
5 Years Return %PE RatioProfit Margin %
Amicus Therapeutics Inc image
Amicus Therapeutics Inc
BUY$4.5B45.47%NA-4.28%
Alnylam Pharmaceuticals Inc image
Alnylam Pharmaceuticals Inc
BUY$41.3B122.97%133.478.45%
Vertex Pharmaceuticals Inc image
Vertex Pharmaceuticals Inc
BUY$110.8B101.1%28.4232.94%
BeiGene, Ltd. image
BeiGene, Ltd.
NA$37.2BNA131.655.37%
Regeneron Pharmaceuticals Inc image
Regeneron Pharmaceuticals Inc
BUY$78.9B49.34%17.9831.41%

Stock Returns calculator for Amicus Therapeutics Inc Stock including INR - Dollar returns

The Amicus Therapeutics Inc stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Impact: The bonus return you make when the US Dollar rises against the Rupee; calculated on the full amount you walk away with, not just what you invested in.

Investment Value

₹1,00,000

  • 1Y

  • 3Y

  • 5Y

  • 7Y

  • 10Y

Amicus Therapeutics Inc investment value today

Current value as on today

₹2,29,349

Returns

₹1,29,349

(+129.35%)

Returns from Amicus Therapeutics Inc Stock

₹1,11,713 (+111.71%)

Dollar Impact

₹17,636 (+17.64%)

Analyst Recommendation on Amicus Therapeutics Inc Stock

Based on 17 analysts

BUY

76.47%

Buy

23.53%

Hold

0.00%

Sell

Based on 17 analysts, 76.47% of analysts recommend a 'BUY' rating for Amicus Therapeutics Inc. Average target price of $14.5

Amicus Therapeutics Inc Share Price Target

Get share price movements and forecasts by analysts on Amicus Therapeutics Inc.

What analysts predicted

0.28%UPSIDE

Target Price

$14.5

Current Price

$14.46

Analyzed by

17 Analysts

Target

$14.50

Amicus Therapeutics Inc target price $14.5, a slight upside of 0.28% compared to current price of $14.46. According to 17 analysts rating.

Amicus Therapeutics Inc Stock’s Investor Sentiment and Interest

Search interest for Amicus Therapeutics Inc Stock has decreased by -36% in the last 30 days, reflecting a downward trend in search activity.

Time period: to

Change:-36% versus previous 30 day period

Amicus Therapeutics Inc Quarterly Profit & Loss

All numbers in Millions USD

Sep 2023
Dec 2023
Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Total Revenue
103
115
110
126
141
149
125
154
169
185
Gross Profit
93
103
96
115
128
134
113
139
147
156
Operating Income
-17
-3
-27
14
21
15
-7
-9
34
15
EBITDA
-9
-16
-28
14
21
21
-4
-5
47
16
Interest Expense
12
12
12
12
12
11
11
11
11
11
Depreciation
2
2
2
2
2
2
1
1
1
1
Income Before Tax
-24
-31
-43
0
6
7
-18
-19
34
3
Income Tax Expense
-3
2
4
15
13
-6
3
5
16
1
Net Income
-21
-33
-48
-15
-6
14
-21
-24
17
1
Net Profit Margin
-20.85%
-29.41%
-43.86%
-12.39%
-4.75%
9.85%
-17.31%
-15.79%
10.24%
0.91%

Amicus Therapeutics Inc Annual Profit & Loss

All numbers in Millions USD

Dec 2016
Dec 2017
Dec 2018
Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Total Revenue
4
36
91
182
260
305
329
399
528
634
Gross Profit
4
30
76
160
229
271
290
362
475
553
Operating Income
-181
-441
-328
-304
-246
-206
-212
-77
24
34
EBITDA
-195
-428
-322
-332
-242
-202
-199
-92
29
53
Interest Expense
5
17
22
18
22
32
37
50
49
46
Depreciation
-
3
4
4
8
6
5
7
8
7
Income Before Tax
-203
-449
-349
-355
-274
-241
-242
-150
-28
0
Income Tax Expense
-3
-165
0
0
2
8
-5
1
27
27
Net Income
-200
-284
-348
-356
-276
-250
-236
-151
-56
-27
Net Profit Margin
-4034.73%
-769.03%
-382.48%
-195.56%
-106.12%
-81.98%
-71.85%
-37.96%
-10.62%
-4.27%

Amicus Therapeutics Inc Quarterly Cash Flow

All numbers in Millions USD

Dec 2023
Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Net Income
-33
-48
-15
-6
14
-21
-24
17
1
Operating Cash Flow
3
-29
22
-22
-3
7
-26
35
16
Investing Cash Flow
-23
7
-21
34
-20
-32
-5
-1
-6
Financing Cash Flow
8
-13
0
18
1
-11
0
-1
14
Change in Cash
-16
-37
0
24
-20
-31
-22
31
23

Amicus Therapeutics Inc Annual Cash Flow

All numbers in Millions USD

Dec 2017
Dec 2018
Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Net Income
-284
-348
-356
-276
-250
-236
-151
-56
-27
Operating Cash Flow
-215
-299
-250
-233
-202
-166
-69
-33
33
Investing Cash Flow
-171
-121
95
-13
78
92
98
0
-46
Financing Cash Flow
247
450
217
262
212
-7
61
5
0
Change in Cash
-137
31
63
19
83
-96
96
-33
0

Global Institutional Holdings in Amicus Therapeutics Inc

Funds
Holdings
Balyasny Asset Management LLC
1.63%
Macquarie Group Ltd
1.45%
Citadel Advisors Llc
2.63%
JPMorgan Chase & Co
1.35%
Rice Hall James & Associates, LLC
1.12%
See all

Amicus Therapeutics Inc News & Key Events

    Insights on Amicus Therapeutics Inc

    Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

    • imgPOSITIVE IMPACT

      Price Rise

      img

      In the last 6 months, FOLD stock has moved up by 79.9%

    • imgPOSITIVE IMPACT

      Best in 1 Year

      img

      In the last 1 year, FOLD has outperformed top 5 stocks with highest market-cap in its industry

    • imgPOSITIVE IMPACT

      Revenue Rich

      img

      Revenue is up for the last 4 quarters, 125.24M → 185.21M (in $), with an average increase of 12.1% per quarter

    • imgNO EFFECT

      Against Peers

      img

      In the last 3 years, Alnylam Pharmaceuticals, Inc. has given 25.3% return, outperforming this stock by 1.5%

    • imgNEGATIVE IMPACT

      Profit Down

      img

      Netprofit is down for the last 2 quarters, 17.30M → 1.69M (in $), with an average decrease of 90.2% per quarter

    About Amicus Therapeutics Inc

    Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering novel medicines for rare diseases in the United States and internationally. The company's commercial product and product candidates consist of Galafold, an orally administered monotherapy for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; Pombiliti + Opfolda, a novel two-component treatment program for adults living with late-onset Pompe disease; and DMX-200, a small molecule inhibitor of the chemokine receptor 2 that is in a pivotal Phase 3 study for the treatment of focal segmental glomerulosclerosis (FSGS) kidney disease. It has collaboration and license agreement with GlaxoSmithKline to develop and commercialize Galafold; and Dimerix Limited for the commercialization of DMX-200 for the treatment of FSGS and other indications. Amicus Therapeutics, Inc. was incorporated in 2002 and is headquartered in Princeton, New Jersey.
    OrganisationAmicus Therapeutics Inc
    Headquarters47 Hulfish Street, Princeton, NJ, United States, 08542
    IndustryBiotechnology
    CEOMr. Bradley L. Campbell M.B.A.
    E-voting on sharesClick here to vote

    Key Management of Amicus Therapeutics Inc

    Name

    Title

    Dr. Jeffrey P. Castelli Ph.D.

    Chief Development Officer

    Mr. Andrew Faughnan

    Vice President of Investor Relations

    Mr. Brendan McEvoy

    Executive Director of External Communications

    Mr. Simon Nicolas Reade Harford

    Chief Financial Officer

    Ms. Ellen S. Rosenberg J.D.

    Chief Legal Officer & Corporate Secretary

    Ms. Samantha L. Prout

    Chief Accounting Officer & Controller

    Dr. Jill Weimer Ph.D.

    Chief Science Officer

    Mr. Patrik S. Florencio Esq.

    Global Chief Compliance & Risk Officer

    Mr. Bradley L. Campbell M.B.A.

    CEO, President & Director

    Mr. David M. Clark

    Chief People Officer

    FAQs

    What is Amicus Therapeutics Inc share price today?

    Amicus Therapeutics Inc share price today is $14.46 as on at the close of the market. Amicus Therapeutics Inc share today touched a day high of $14.46 and a low of $14.45.

    What is the 52 week high and 52 week low for Amicus Therapeutics Inc share?

    Amicus Therapeutics Inc share touched a 52 week high of $14.48 on and a 52 week low of $5.51 on . Amicus Therapeutics Inc stock price today i.e. is closed at $14.46,which is 0.14% down from its 52 week high and 162.43% up from its 52 week low.

    What is Amicus Therapeutics Inc's market capitalisation today?

    Amicus Therapeutics Inc market capitalisation is $0.00T as on .

    How to invest in Amicus Therapeutics Inc Stock (FOLD) from India?

    1. Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
    2. Step 2: Search for Amicus Therapeutics Inc on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Amicus Therapeutics Inc Shares that will get you 0.1037 shares as per Amicus Therapeutics Inc share price of $14.46 per share as on April 18, 2026 at 1:29 am IST.

    What is the minimum amount required to buy Amicus Therapeutics Inc Stock (FOLD) from India?

    Indian investors can start investing in Amicus Therapeutics Inc (FOLD) shares with as little as ₹92.575 or $1 (as of ) using the INDmoney app.
    For example: If you want to invest $10 or ₹925.75 in Amicus Therapeutics Inc stock (as per the Rupee-Dollar exchange rate as on ). Based on Amicus Therapeutics Inc share’s latest price of $14.46 as on April 18, 2026 at 1:29 am IST, you will get 0.6916 shares of Amicus Therapeutics Inc. Learn more about fractional shares .

    What are the returns that Amicus Therapeutics Inc has given to Indian investors in the last 5 years?

    Amicus Therapeutics Inc stock has given 45.47% share price returns and 24.75% dollar appreciation to an Indian investor in the last 5 years.
    Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?